BrainsWay Ltd. achieved final positive results from its pivotal multicenter trial on the safety and efficacy of the Company’s H4 Deep transcranial magnetic stimulation system

Zygosid-50, a drug under development in Israel, could be the first to treat type 2 diabetes by restoring the body’s insulin sensitivity, without side effects.

Augmedics, a pioneer in augmented reality surgical image guidance, has announced U.S. Food and Drug Administration (FDA) 510(k) clearance and the U.S. launch of its

Following achievement of an important milestone for Stem-Cell based cancer treatments resistance diagnostics, Jerusalem based NewStem received a further $ 1 million follow-on investment from

Raziel Therapeutics a clinical-stage pharmaceutical company announces a $22 million Series C preferred stock financing led by Pontifax, with the participation of existing investors Dr. Shmuel Cabilly

Concenter Biopharma is working on a novel drug to eliminate type 2 diabetes with no side effects. The drug dramatically lowers insulin resistance, the major

During the MEDICA exhibition in Düsseldorf, Germany, on November 18, Salignostics present for the first time the world’s first saliva rapid pregnancy test, the SaliStick. Salistick provides

Entera Bio‘s platform technology enables oral therapies based on molecules that would otherwise undergo gastric degradation and have limited or no bioavailability. By transforming injectable

Jerusalem based Pepticom, a leader in artificial intelligence peptide drug discovery,  has secured $5 million in Series A funding from the Chartered Group. Pepticom’s unique